Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Why ordering takeout or calling the dog walker might lead to a happier relationship - 2German finance minister sees advantages of smartphones in schools
- 3My Excursion to Monetary Autonomy: Awesome ways to save cash
- 4Instructions to Figure out the Various Phases of Cellular breakdown in the lungs
- 5What's an atmospheric river? AP explains the weather phenomenon
- The most effective method to Boost Eco-friendliness in Your Volvo XC40
- Manual for Tracking down Spending plan Agreeable Travel Objections
- Ukraine to get up to 100 French-made Rafale fighter jets
- Cells have more mini ‘organs’ than researchers thought − unbound by membranes, these rogue organelles challenge biology’s fundamentals
- Famous Network programs in Europe and America
- The 10 Most Compelling Forerunners in Innovation
- Signature Scents: A Manual for Outstanding Fragrances
- 4 Family SUVs: Joining Solace and Style
- Doritos and Cheetos dial back the bright orange in new versions without artificial ingredients
